Objective: The recently detected ERG rearrangement revealed as a recurrent and prevalent prostate cancer (PCa) specific event. To detect this alteration, FISH is the method of choice. However, FISH harbors disadvantages for widespread adoption in clinical practice. Subsequently, the chromogenic in-situ hybridization (CISH) and the enzymatic metallography silver in-situ hybridization (SISH) emerged as promising bright-field alternatives. We aimed to develop a combined CISH and SISH (CS-ISH) gene break-apart assay on the example of the ERG gene. Method: We assessed and compared 178 PCa and 10 benign specimens for their ERG rearrangement status applying a dual-colour FISH and CS-ISH ERG break-apart assay on consecutive sections. Results: We observed a highly significant concordance (97,7 %) between FISH-based and CS-ISH-based results (Pearson's correlation coefficient 0.955, P<0.001). Conclusion: We demonstrate that the ERG rearrangement status can reliably be assesed by CS-ISH. Further, we confirm that the CS-ISH technique combines the accuracy and precision of FISH with the ease of bright field microscopy. We developed a tool which allows a broad spectrum of applicants to study the biological role and clinical utilization of ERG rearrangements in PCa. Moreoever, our study is the first proof-of-principle for bright-field CS-ISH gene fusion or break-apart assays.